Dr. Reddy’s Expands into Hormone Therapy with $32.15M Acquisition

Dr. Reddy's Laboratories has strengthened its India portfolio by acquiring key hormone therapy brands, marking a strategic entry into the Hormone Replacement Therapy (HRT) segment. Key Highlights • Acquired trademarks and related assets of Progynova® and Cyclo-Progynova® for USD 32.15 million • Entry into the Hormone Replacement Therapy (HRT) market in India • Progynova® is the leading brand in the Estradiol segment in India • Brand reported sales of approximately ₹100 crore (IQVIA MAT December 2025) Why This Matters The acquisition provides immediate scale in a niche but growing therapeutic category. HRT is a specialized segment with strong brand loyalty and recurring demand, which can enhance portfolio diversification and margin profile. Impact Assessment Positive. The deal strengthens Dr. Reddy’s domestic branded portfolio and adds an established revenue stream in a high-value therapy area. Learning Outcome Strategic brand acquisitions in pharma allow companies to expand into new therapeutic segments quickly without long development timelines. Established brands with strong market share can immediately contribute to revenue and profitability.